Theravance Biopharma Files 2024 10-K
Ticker: TBPH · Form: 10-K · Filed: Mar 7, 2025 · CIK: 1583107
| Field | Detail |
|---|---|
| Company | Theravance Biopharma, Inc. (TBPH) |
| Form Type | 10-K |
| Filed Date | Mar 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, share-repurchase
TL;DR
TBPH filed 2024 10-K: shows share buybacks, lease details, and retained earnings. All good.
AI Summary
Theravance Biopharma, Inc. filed its 2024 10-K on March 7, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The filing details various financial aspects, including share repurchase plans, lease liabilities, and retained earnings. The company's business address is UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, KY1-1104.
Why It Matters
This filing provides investors with a comprehensive overview of Theravance Biopharma's financial health and operational activities for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: low — The provided snippet is a standard 10-K filing header and does not contain specific financial risks or operational challenges.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-07 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Theravance Biopharma, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-07 (date) — Filing date
- UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, KY1-1104 (address) — Business and mailing address
FAQ
What were Theravance Biopharma's share repurchase activities during the reported periods?
Theravance Biopharma had open market share repurchase plans active from January 1, 2024, to December 31, 2024, and from January 1, 2023, to December 31, 2023. An earlier plan was active from September 1, 2022, to January 31, 2024.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
When was this 10-K filing submitted?
This 10-K filing was submitted on March 7, 2025.
What are the reported lease liabilities?
The filing references current and non-current operating lease liabilities, indicating the company has ongoing lease obligations.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code for Theravance Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 7, 2025 regarding Theravance Biopharma, Inc. (TBPH).